MYCO.NE - Mydecine Innovations Group Inc.

Cboe CA - Cboe CA Real Time Price. Currency in CAD
0.2400
+0.0100 (+4.35%)
At close: 03:47PM EDT
Stock chart is not supported by your current browser
Previous Close0.2300
Open0.2150
Bid0.1500 x N/A
Ask0.2550 x N/A
Day's Range0.1700 - 0.2400
52 Week Range0.1700 - 1.0300
Volume122,743
Avg. Volume111,318
Market Cap7.449M
Beta (5Y Monthly)3.34
PE Ratio (TTM)N/A
EPS (TTM)-0.4400
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors

    VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party

  • GlobeNewswire

    Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023

    VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the three months ended March 31, 2023. Financial Results for the Three Months Ended March 31, 2023 Net Loss: The net loss a

  • GlobeNewswire

    Mydecine Reports its 2023 Annual General Shareholders' Meeting Results

    VANCOUVER, British Columbia, May 10, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce the results of voting at its annual general and special meeting (“AGSM”) of shareholders which was held on Friday, May 5, 2023, by con

  • GlobeNewswire

    Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues

    VANCOUVER, British Columbia, April 24, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is glad to share promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. The mice model data indicates c

  • CNW Group

    MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated March 10, 2023 and the subsequent filing of

  • CNW Group

    MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor (the "Investor") dated March 10, 2023, the Compan

  • GlobeNewswire

    Mydecine Innovations Group Provides Corporate Update

    VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has announced that it has improved its financial position, significantly reduced cash burn, increased efficiencies and expanded its intellectual property p

  • GlobeNewswire

    Mydecine Reports Financial Results for the Year Ended December 2022

    DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the years ended December 31, 2022 and 2021. Company Highlights In 2022, Mydecine continued to define its focus and clinical trial execution strategy. The Company reached several milestones with the goal

  • CNW Group

    MYDECINE INNOVATIONS GROUP ANNOUNCES COMMON SHARE SUBSCRIPTION AGREEMENT

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, today announced that it has entered into a third Common Share Subscription Agreement, effective March 10th, 2023 (the "Subscription Agreement") with a third-party investor in the Company (the "Investor"). The Subscri

  • GlobeNewswire

    Mydecine Announces Debt Settlements

    DENVER, March 06, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements (the “Debt Settlements”) for debt owed to certain arms-length creditors, service providers and debtors of the Company (collecti

  • GlobeNewswire

    Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.

    DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address addiction and mental health, is pleased to announce that, further to its news release dated September 1, 2022, it has closed the sale of all of the issued and outstanding shares of its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap”

  • GlobeNewswire

    Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022

    DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported company highlights and financial results for the nine months ended September 30, 2022. Company Highlights In 2022, Mydecine continued to define its focus and clinical trial execution strategy. The Company reached several milestones with the goal to

  • CNW Group

    MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT AND WELCOMES NEW CFO

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement (the "Subscription Agreement") with a third-party investor dated August 26, 2022 and the subsequent filing o

  • CNW Group

    IIROC Trade Resumption - MYCO

    Trading resumes in:

  • GlobeNewswire

    Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.

    DENVER, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that the company has signed an LOI for the sale of its digital technology subsidiary, Mindleap Health Inc. to PanGenomic Health Inc. (“Pangenomic”). "We

  • CNW Group

    IIROC Trading Halt - MYCO

    The following issues have been halted by IIROC:

  • GlobeNewswire

    Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

    DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that it has entered into a Common Share Subscription Agreement (the “Subscription Agreement”) with a third-party investor in the Company (the “Subscriber”

  • GlobeNewswire

    Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

    DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months ended June 30, 2022. Financial Results for the Six Months Ended June 30, 2022 Net Loss: The net loss attributable to common stockholders was $8.09 million, from operations, or a basic and diluted loss per share

  • CNW Group

    MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

    Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale have recently resigned as directors of the Company.

  • GlobeNewswire

    Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

    Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructureDENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been speci

  • GlobeNewswire

    U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

    DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product. The Investigator Initiated trial is funded by a near $4 million grant